Background: Chronic Spontaneous Urticaria (CSU) is a disease presenting typical wheals
characterized by itching, angioedema or both. Although CU is, by appearance, a relatively “simple”
disease, yet it has a devastating effect on those suffering due to its immense social implications.
Aims: The aim of the present study was to investigate the effect of omalizumab in the treatment of
CSU. In particular, gender, co-administration of drugs and comorbidities were taken into account.
Materials and Methods: 108 patients (25 Males/83 Females) admitted to our department were diagnosed
with CSU and were treated for 30 months. CSU was estimated on a score basis, which was
used in order to define disease severity. The mean total CSU score and the mean CSU score of the
first trimester, as well as the first semester, were calculated. Patients were treated with omalizumab,
and in several cases, with co-administration of dapsone, cyclosporine and anti-histamines.
Results: Females manifested significantly higher scores as compared to males. Further on, patients
who relapsed manifested significantly higher scores during the whole time course, as well as at the
end of the first semester.
Conclusion: Females are more prone to CSU. Although CSU scores in patients with remission, relapse
and poor response manifested no significant difference at diagnosis, relapsed patients manifested
higher CSU scores in the first semester. Therefore, the first semester of treatment is probably critical
for the final patient outcome. Further studies are necessary in order to understand the mechanisms
of CSU for better treatment and prognosis.